Articles tagged with Breast Cancer
A multi-institutional international study has revealed new information about the interaction between long non-coding RNAs and HIF-1 signaling pathways in triple-negative breast cancer. The study identifies four previously unknown phosphorylation sites, which predict a worse outcome for TNBC patients, suggesting that these sites could s...
Research teams confirm biennial mammography for women aged 50-74 offers favorable balance of benefits to harm. Screening frequency impacts mortality and false positives, with biennial screening reducing breast cancer deaths by 25.8%.
Researchers at Boston University School of Medicine identified a metastasis suppressor gene called serum deprivation response (SDPR), which plays a role in breast cancer progression. Over-expression of SDPR reduces the incidence of metastatic disease in models of aggressive, metastatic breast cancer cells.
Experts argue that cancer screening has never been shown to 'save lives' due to reduced overall mortality rates. Harms associated with screening, such as overdiagnosis and false positives, are significant concerns. The authors call for higher standards of evidence and consideration of harms in cancer screening.
A new injectable agent, LUM015, has been tested in a trial and found to identify cancerous tissue in human patients without adverse effects. The technology could significantly change the treatment of sarcoma by allowing surgeons to remove 100% of the tumor on the first attempt.
A study of 200,000 twin individuals found an increased cancer risk among those whose co-twin was diagnosed with cancer. The risks varied by type and were higher for monozygotic twins.
A recent study at MD Anderson Cancer Center found that dietary sugar, particularly fructose, can increase the risk of breast cancer tumors and lung metastasis in mice. The research suggests that high sugar intake activates an inflammatory pathway called 12-LOX, leading to increased tumor growth and spread.
A study published in Plastic and Reconstructive Surgery found that long travel distances continue to be a significant barrier to breast reconstruction after mastectomy for US women. Reconstruction rates varied by type of hospital and distance traveled, with greater disparities observed at academic hospitals and high-volume centers.
Researchers have identified a specific weakness in the immune system of patients with HER2-positive breast cancer, which may be corrected with a HER2-targeted vaccine. T cells from patients with recurrent cancer showed weaker response to the HER2 receptor protein compared to those without recurrence.
A novel PET/CT imaging method has been shown to accurately measure HER2 expression in metastatic breast cancer, potentially leading to more optimal individualized treatments. This non-invasive technique may one day substitute traditional tissue sampling.
The new oral drug Palbociclib has shown promise in combating various types of cancer beyond breast cancer, including lymphoma, sarcoma, and teratoma. Early trials have demonstrated its effectiveness in slowing tumor growth and improving survival rates in patients with these conditions.
A study published in JNCI Journal of the National Cancer Institute found that ultrasound sensitivity is comparable to mammography, but with a higher false-positive rate. The researchers suggest considering ultrasound as a supplemental test for women with dense breasts or those unable to tolerate MRI.
A new American Cancer Society study reveals that excess medical expenditures and productivity losses vary significantly among cancer survivors by age and cancer site. Nonelderly survivors of colorectal and breast cancers experience higher annual expenditures compared to those without a cancer history.
A study found that women with breast cancer who received chemotherapy and triptorelin had a higher long-term probability of ovarian function recovery without affecting pregnancy rates or disease-free survival. The treatment showed modest benefits regarding potential prevention of treatment-associated infertility.
A new analysis of genetic information from over 4,000 cancer cases reveals rare germline mutations in 114 genes associated with cancer. The study found varying frequencies of these mutations across 12 cancer types, including a surprising inherited component to stomach cancer.
A team at Cold Spring Harbor Laboratory has discovered a novel drug that targets an abnormal RNA molecule called Malat1 in metastatic breast cancer. The drug reduces tumor growth by 70% and prevents metastasis, suggesting that targeting this RNA may be a promising therapeutic approach for treating aggressive breast cancer.
A plant virus shell triggers a potent immune response in mice, wiping out tumors and preventing metastatic disease. The treatment, using cowpea mosaic virus nanoparticles, shows promise as an effective and low-toxicity alternative to traditional therapies.
A study found that postmenopausal women with periodontal disease were more likely to develop breast cancer than those without the condition. The risk was particularly high among women who had quit smoking recently, suggesting a potential link between bacterial exposure and breast cancer risk.
Researchers at NYU College of Nursing developed a method to detect breast cancer-related lymphedema by counting symptoms, showing high sensitivity and specificity. The study found that a diagnostic cutoff of three symptoms can distinguish healthy adults from those with lymphedema with 94% sensitivity.
The PALOMA3 trial confirms the efficacy of combining palbociclib with fulvestrant in Asian patients with hormone receptor-positive, HER2-negative advanced breast cancer. The combination shows positive results in progression-free survival for postmenopausal women, while a longer follow-up is needed to confirm overall survival.
A NYU nursing study found that obesity is a significant risk factor for breast cancer-related lymphedema, which can be managed with early and appropriate treatment. The study suggests that general instructions on nutrition-balanced diets and physical activities can help maintain pre-surgery weight.
Researchers at Berkeley Lab have created a clinically relevant mouse model of human breast cancer, bearing resemblance to the most prevalent form of breast cancer. The model, '184AA3,' will enable testing of therapies for aggressive ER+ breast cancers and studying the biology and etiology of luminal cancers.
A new study by TSRI scientists suggests a potent new therapeutic approach for hard-to-treat breast cancers, targeting the enzyme casein kinase 1´ (CK1´), which is overexpressed in many breast cancer types. The study found that a highly selective and potent CK1´ inhibitor, SR-3029, triggers rapid tumor cell death.
Liquid biopsies may help predict treatment responses and genetic mutations that impact prognosis in advanced breast cancer. The tests analyzed tumor DNA in blood samples, revealing potential benefits and risks of combining therapies.
The T-DM1 trial showed that the treatment increased median overall survival for heavily pretreated HER2-positive breast cancer patients by 22.7 months compared to treatment of physician's choice. The study also found reduced incidence of grade 3 or higher adverse events among those assigned T-DM1.
Researchers found similar outcomes for disease recurrence between women taking anastrozole and those taking tamoxifen, but noted significant differences in side effects. Women on anastrozole had fewer endometrial and ovarian cancers, while those on tamoxifen experienced more major thromboembolic events.
A study of postmenopausal women with DCIS found that anastrozole and tamoxifen caused different symptom profiles. Hot flashes were more common in the tamoxifen group, while musculoskeletal complaints and vaginal problems were more prevalent in those receiving anastrozole.
Studies found that patients with delayed breast cancer surgery and chemotherapy had poorer overall and disease-specific survival rates. A delay of up to 90 days in receiving chemotherapy was associated with no adverse outcomes, but prolonged delays led to increased risks of death from the disease.
Researchers found that D538G and Y537S mutations in the estrogen receptor 1 (ESR1) gene are common in ER-positive breast cancer patients, associated with poorer outcomes and reduced response to everolimus treatment. The study suggests that these mutations may predict different responses to therapies.
Researchers investigated the reasons behind tamoxifen's varying efficacy in women. Genetic variants on the CYP2D6 gene were initially linked to worse survival rates, but subsequent studies found no association. Advanced statistical modeling suggests that genotyping errors may have contributed to these findings.
A recent study suggests that elevated levels of the enzyme APOBEC3B drive tamoxifen resistance in estrogen receptor-positive breast cancer. Higher APOBEC3B levels were associated with shorter progression-free survival times.
A new study from the University of Texas MD Anderson Cancer Center found that mastectomy plus reconstruction has the highest rate of complications and complication-related costs among guideline-concordant therapies for early breast cancer. The study also revealed that this treatment option is the most expensive in younger patients, wit...
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A population-based study of 37,207 patients found that those who received breast-conserving surgery plus radiation therapy had improved overall survival after 10 years compared to those who received mastectomy without radiation. BCT was also associated with fewer regional recurrences and distant metastases.
A new study from MD Anderson Cancer Center found that delaying chemotherapy after surgery increases the risk of death for breast cancer patients, particularly those with triple-negative breast cancer. Patients who start treatment within 90 days have a lower risk of death compared to those who delay it.
Dr. Norman Wolmark will present the William L. McGuire Memorial Lecture on the NSABP Clinical Trials' impact on early breast cancer management. Established in 1992, the McGuire Lectureship commemorates Dr. William McGuire's contributions to oncology.
A recent study has found that mastectomy and reconstruction have higher complication rates and costs compared to lumpectomy and radiation. For younger women with private insurance, the risk of complications from mast+recon was two times higher than lump+WBI after adjusting for other differences in patients and treatment.
A phase III trial found that women with luminal A subtype of breast cancer had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy. In contrast, patients with non-luminal A subtypes who received chemotherapy were 50% less likely to have their disease recur in 10 years.
Patients with stage 2 or 3 triple-negative breast cancer (TNBC) who achieved a pathologic complete response (pCR) after presurgery chemotherapy had significantly improved event-free and overall survival compared to those with more than minimal residual invasive disease. This benefit was observed in patients with larger tumors or lymph ...
The ABCSG-18 clinical trial found that adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival in postmenopausal patients with HR+ breast cancer. After a median follow-up of four years, patients assigned denosumab had an 18 percent reduced risk of disease recurring compared with those assigned placebo.
A phase III trial found that capecitabine improved disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy. The study showed a 30% reduced risk of disease recurrence compared to standard therapy.
Results of a phase 1b clinical trial show ONT-380 achieves at least stable disease in 58% of patients with metastatic HER2+ breast cancer, including 11 partial responses and one complete response in patients with brain metastases.
A landmark clinical trial shows that beta blockers and ACE inhibitors effectively prevent heart function drop in patients with early-stage breast cancer. The study suggests these medications can improve breast cancer survival rates by limiting interruptions to chemotherapy treatment.
Recent studies present new data on the myRisk Hereditary Cancer test, highlighting its ability to identify patients with deleterious mutations who may have been missed by traditional genetic testing. The test demonstrated a significant increase in identifying BRCA-related mutations among those tested without BRCA1/2 results.
Adding carboplatin to presurgery chemotherapy significantly improved disease-free survival rates for patients with triple-negative breast cancer (TNBC). The study found that patients with pathologic complete responses had the lowest risk of relapse, supporting the use of carboplatin as a standard part of neoadjuvant therapy regimens.
A phase IIR/III clinical trial investigates whether surgery or stereotactic body radiation can control metastasis while continuing breast cancer therapy. Researchers aim to define parameters for determining which patients benefit from this 'weeding the garden' approach.
Researchers found that telomeres slow down and sometimes even reverse with weight loss and exercise in breast cancer survivors. Higher body fat levels are associated with shorter telomere length.
New studies from the University of Pennsylvania School of Medicine found that aspirin use is not associated with improved clinical outcomes or survival among breast cancer patients. However, another study suggests that aspirin may help reduce breast tissue density, which could lead to earlier detection of some breast cancers.
A study of over 21,000 women found that only 1 in 6 with increased breast cancer risk take preventive medication, despite being eligible for clinical trials. Most women who started the medication continued taking it for at least a year, but usage declined over time.
Researchers found that combining palbociclib with paclitaxel shrank tumors in nearly half of patients with estrogen-receptor positive breast cancer. The combination appears to be safe and may offer benefits over paclitaxel alone, suggesting a larger clinical trial is warranted.
Researchers found that losing CD73 enzyme promotes tumor growth and progression in endometrial cancer by disrupting adenosine signaling, which normally regulates tissue function. The study provides new insights into the role of CD73 in cancer development.
A phase 1 clinical trial found that enzalutamide is active and well-tolerated alone and with fulvestrant in patients with advanced breast cancer. The study supports a larger trial of the combination, building on promising preclinical data and targeting androgen receptors in breast cancer.
A study found that breast cancer survivors with therapy-related leukemia often have inherited cancer susceptibility and gene mutations. Researchers suggest a long-term follow-up study to understand the impact of these genes on leukemia risk, enabling personalized conversations about treatment benefits and risks.
A new gene therapy platform uses a hydrogel and self-assembled nanoparticles to deliver microRNAs that suppress tumor tissue, increasing dosage at the site while reducing systemic side effects. The approach has shown promising results in shrinking tumors by nearly 90% in pre-clinical models.
A mindfulness-based stress reduction program has been shown to improve attention and reduce mistakes on difficult cognitive tasks in breast and colorectal cancer survivors. The program, known as MBSR, provides a creative solution for managing cancer-related cognitive impairment, which can be incapacitating.
UC Davis researchers have made significant progress in tumor treatment by combining guided ultrasound with nanoparticle chemotherapy, resulting in improved survival and consistent cure rates. The technique allows for complete destruction of tumors without thermal damage to surrounding tissue.
Research by Allison Cleary reveals that breast cancer cells work together to promote tumor growth, contradicting the long-held assumption of competitive interactions within tumors. Her findings have implications for developing novel treatments that target cooperative interactions in human breast cancers.
Researchers have isolated four distinct circulating tumor cell subsets, one of which marks genes known to be directly implicated in tumor cell dormancy. These findings may lead to a preventive treatment for metastatic cancer cells and provide insights into the mechanisms of breast cancer recurrence.
A study of over 20,000 women with stage IV breast cancer found improved survival rates, especially among those who received initial breast surgery. The median survival increased from 20 to 26 months, and age, tumor size, hormone receptor status, and year of diagnosis were associated with prolonged survival.
A new study suggests that breast density alone is not a significant risk factor for breast cancer in postmenopausal women. The study found no significant difference in breast density between breast cancer patients and control groups.